cyclic heptapeptide comes up often in conversation and rarely with the context attached. Here we lay out the basics in order, then work through the practical considerations.
Updated 2026-04-10. Numbers and descriptions here follow the published literature rather than marketing material.
Research interest has centred on photoprotection and pigmentation, with a smaller body of work on appetite and sexual function. Published human data remain limited to small, frequently uncontrolled studies, and the compound has never received marketing approval from a national medicines regulator. Most laboratory work treats it as a pharmacological tool for probing melanocortin signalling in cell culture or animal models. Whether pigmentation changes observed in people translate into measurable protection against ultraviolet-induced DNA damage remains an open question.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, the naturally occurring peptide involved in pigmentation signalling. Its sequence is conventionally written as Ac-Nle-cyclo[Asp-His-D-Phe-Arg-Trp-Lys]-NH2, with a lactam bridge joining the aspartate side chain to the lysine side chain. The empirical formula is C50H69N15O9 and the monoisotopic mass lies near 1023.5 daltons. N-terminal acetylation and the D-configured phenylalanine both increase resistance to enzymatic breakdown compared with the parent hormone.
Pharmacologically, melanotan-2 behaves as a non-selective agonist across the melanocortin receptor family. Binding at MC1R on dermal melanocytes promotes eumelanin synthesis, which underlies the tanning response described in early human work. Activity at the centrally expressed MC4R receptor is associated with reported effects on appetite and erectile function. Because the peptide does not discriminate strongly among receptor subtypes, attributing any single observed effect to one receptor pathway is generally not possible without selective antagonists or receptor knockout models.
Melanotan-2 is frequently confused with afamelanotide, a linear analogue authorised in the European Union for erythropoietic protoporphyria. The two compounds differ in chain length, ring structure and receptor selectivity, so findings for one cannot be transferred directly to the other. Published controlled human data on melanotan-2 remain sparse, and much of what circulates online derives from small studies or unpublished reports. Questions about effect size, dose-response behaviour and long-term safety therefore remain unresolved.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone. Its sequence incorporates a lactam bridge that constrains the peptide into a ring, which increases resistance to enzymatic breakdown relative to the natural hormone. Researchers at the University of Arizona synthesised the compound in the late 1980s and early 1990s while studying pigmentation pathways. It has never received marketing approval from any national medicines regulator. In the scientific literature it is usually described as a laboratory research reagent rather than a therapeutic product.
The peptide acts as a non-selective agonist at melanocortin receptors, showing affinity for MC1R, MC3R, MC4R and MC5R. Activation of MC1R on melanocytes drives the conversion of tyrosine into melanin and shifts production toward the darker eumelanin form. MC4R signalling in the central nervous system is linked to appetite and energy balance, which helps explain why reduced food intake appeared in early human studies. Effects on MC4R and on vascular tone also account for the erectile responses recorded as unexpected findings in those same trials.
| Property | Value | Notes |
|---|---|---|
| Common synonyms | Melanotan II; MT-II; N-acetyl-norleucyl-cyclo[Asp-His-D-Phe-Arg-Trp-Lys] amide | Naming follows peptide convention; the numeral distinguishes it from melanotan-1 |
| Molecular formula | C50H69N15O9 | Includes the lactam bridge; no counter-ion assumed |
| Monoisotopic mass | 1023.53 Da | Free base; salts and counter-ions shift the observed value |
| Appearance | White to off-white lyophilised powder | Batch-to-batch colour variation is not itself proof of impurity |
| Typical analytical method | RP-HPLC purity determination with ESI-MS identity confirmation | Retention time alone does not establish sequence identity |
The compound was developed in the late 1980s and 1990s by academic researchers investigating photoprotection. The rationale held that stimulating melanin production might reduce ultraviolet damage to skin and lower skin cancer risk. Early work examined receptor binding, pigment response, and short-term tolerability in small studies. That program did not produce an approved drug, and formal development stalled after early-phase trials. Whether induced pigmentation confers meaningful photoprotection remains an open question.
Outside regulated medicine, melanotan II circulates through online vendors as a research chemical, often marketed for tanning. Products sold this way vary widely in purity, concentration, and labeling accuracy, and independent testing has documented discrepancies. Published reports describe both pigment effects and adverse reactions, including nausea, flushing, and darkening of existing moles. Long-term safety data are sparse, and no large controlled trial has established a risk profile. Questions about cumulative effects on melanocytes remain unresolved in the literature.
Melanotan II is a synthetic peptide analog modeled on alpha-melanocyte-stimulating hormone, a naturally occurring signaling peptide involved in pigmentation. Its structure is a cyclic heptapeptide containing two non-natural substitutions, norleucine at position four and D-phenylalanine at position seven. These modifications resist enzymatic breakdown and extend the molecule's activity relative to the native hormone. The compound binds melanocortin receptors and is studied mainly as a pharmacological tool rather than a therapeutic product. It has never received approval as a medicine in any major jurisdiction.
Structurally, Melanotan-2 retains the core recognition motif of alpha-melanocyte-stimulating hormone while adding a lactam bridge that links two side chains and constrains the molecule into a ring. This modification lowers susceptibility to enzymatic degradation. The compound acts as an agonist at melanocortin receptors, particularly subtypes associated with melanin production. Because the same receptor family influences several physiological processes, researchers note that its activity is not confined to pigmentation alone. Receptor selectivity continues to be examined in published studies.
Melanotan-2 is a synthetic cyclic heptapeptide designed as an analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its sequence incorporates modified residues that increase potency and extend biological activity relative to the native hormone. The compound binds receptors of the melanocortin family and is examined mainly in laboratory research. It does not occur naturally and exists only as a manufactured chemical entity produced by solid-phase synthesis.
The compound emerged from research programs in the 1980s that examined analogues of alpha-melanocyte-stimulating hormone for pigmentation and photoprotection. Investigators modified the native sequence to extend activity duration and potency. A related analogue, afamelanotide, was developed within the same broad line of inquiry and eventually gained approval in certain jurisdictions for a rare light-sensitivity condition. Melanotan-2 itself did not progress through the same regulatory route and has no approved therapeutic indication.
Melanocortin receptors comprise five subtypes with distinct tissue distributions and functions. Melanotan-2 is described in the literature as a non-selective agonist that engages several of these subtypes, including MC1R, MC3R, MC4R, and MC5R. MC1R is the subtype most directly linked to melanin production in skin cells. Because the compound is not subtype-selective, its observed effects in experimental settings are generally attributed to activity across multiple receptor pathways rather than to a single target.
Regulatory treatment varies between countries. Several national medicines agencies have classified the peptide as unapproved, and customs authorities in some jurisdictions seize shipments on that basis. A few jurisdictions channel supply through prescription-only frameworks that do not list the substance by name. Because the material circulates mainly through online vendors, composition and purity are rarely verified before sale. Surveys of unapproved peptide products have reported labels that did not match measured content in a substantial fraction of samples.
Melanotan II is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, a naturally occurring peptide involved in pigmentation signalling. Its structure substitutes a lactam bridge between side chains to increase stability relative to the native hormone. The compound is also known by the shorthand MT-II and by several non-proprietary synonyms used in research catalogues. It is not an approved therapeutic product in any major jurisdiction; material sold under this name is typically offered as a laboratory reagent rather than as a medicine.
== Taxonomy == The death cap is named in Latin as such in the correspondence between the English physician Thomas Browne and Christopher Merrett. It was described by French botanist Sébastien Vaillant in 1727, who gave a succinct phrase name "Fungus phalloides, annulatus, sordide virescens, et patulus" (a phallus-shaped, ring-stemmed, dirty green mushroom with a large 'spreading' cap). In 1821, Elias Magnus Fries described it as Agaricus phalloides, but included all white amanitas within its description. Finally, in 1833, Johann Heinrich Friedrich Link settled on the name Amanita phalloides, after Persoon had named it Amanita viridis 30 years earlier. Although Louis Secretan's use of the name A. phalloides predates Link's, it has been rejected for nomenclatural purposes because Secretan's works did not use binomial nomenclature consistently; some taxonomists have, however, disagreed with this opinion. Amanita phalloides is the type species of Amanita section Phalloideae, a group that contains all of the deadly poisonous Amanita species thus far identified. Most notable of these are the species known as destroying angels, including A. virosa, A. bisporigera, A. ocreata, A. verna, and more than a dozen others. The term "destroying angel" has been applied to A. phalloides at times, but "death cap" is by far the most common vernacular name used in English. Other common names also listed include "stinking amanita" and "deadly amanita". A rarely appearing, all-white form was initially described A. phalloides f. alba by Max Britzelmayr, though its status has been unclear.
=== Structure === Fialuridine is a synthetic pyrimidine nucleoside analogue with the molecular formula C9H10FIN2O5 and a molecular weight of 372.09 g/mol. Structurally, it consists of a substituted pyrimidine base covalently linked to a modified pentose sugar. The base component is a 5-iodo-substituted pyrimidine-2,4-dione ring. The pyrimidine ring is aromatic, containing two carbonyl groups at positions 2 and 4. The uracil derivative also contains an iodine atom at position 5. The attached sugar is a five-membered furanose ring that differs from natural deoxyribose in two ways: it has a fluorine atom at the second carbon (2-deoxy-2-fluoro substitution) and adopts the arabino configuration (fluor pointing up, 3’hydroxyl pointing down). The sugar ring is saturated and non-aromatic. The modified base and sugar are connected via a β-N1 glycosidic bond between the anomeric carbon of the sugar and the N1 nitrogen of the pyrimidine ring. All these structural features correspond to similar pyrimidine analogues.
==== Space disposal ==== Space disposal is attractive because it removes nuclear waste from the planet. It has significant disadvantages, such as the potential for catastrophic failure of a launch vehicle, which could spread radioactive material into the atmosphere and around the world. A high number of launches would be required because no individual rocket would be able to carry very much of the material relative to the total amount that needs to be disposed. This makes the proposal economically impractical and increases the risk of one or more launch failures. To further complicate matters, international agreements on the regulation of such a program would need to be established. Costs and inadequate reliability of modern rocket launch systems for space disposal has been one of the motives for interest in non-rocket spacelaunch systems such as mass drivers, space elevators, and other proposals.
== Other == Rational Emotive Therapy, therapy now referred to as rational emotive behavior therapy Rational Expectations Theory, economic model-consistent expectations Resistance exercise training, a type of physical exercise Retatrutide, an experimental obesity drug developed by Eli Lilly and Company. Reticulum, a constellation abbreviated Ret Reț, a village in Blăjeni Commune, Hunedoara County, Romania
The structure of the People's Armed Police is complex, and has highly varied over time. While the majority of PAP units are involved in standard policing and gendarmerie duties, the PAP has also included at different times unique specialised units. The People's Armed Police was established in 1982, taking over duties from previous units and formations that directly under the command of the People's Liberation Army. The PAP reports directly to the Central Military Commission (CMC) of the Chinese Communist Party (CCP).
Sources: en.wikipedia.org
== History == Pharmaceutical company Johnson & Johnson's Ortho Research Laboratory wrote that case histories of his therapy, "were quite remarkable and your concepts most intriguing" and ICN Pharmaceuticals replied, "The results you have obtained with this drug in the treatment of gangrene have been most spectacular", but DeMarco was never able to commercialize the therapy beyond his own medical practice. Swiss pharmaceutical company Debiopharm S.A. replied, "Drug induced cell regeneration appears to be a revolutionary new form of treatment which is bound to be perceived as highly controversial by several regulatory agencies. We are not in a position to take the considerable time and risk involved in convincing the bureaucrats." Thus although intrigued, the pharmaceutical companies never showed a serious interest in developing his product. Regenerative medicine was a new field at the time and DeMarco likened the companies' antipathy of his discovery to the history of penicillin; although discovered in 1928, penicillin was not mass-produced until 1941 when production became a top priority World War II project to reduce the infection casualty rate. DeMarco's clinical use of a drug not approved by the U.S. Food and Drug Administration came to the attention of regulators in both New Jersey and Pennsylvania, leading to the suspension of his license to practice and the seizure of his supply of procaine hydrochloride, which investigators later found to be contaminated and mislabeled. The New Jersey Department of Health traced 64 cases of infectious hepatitis to Dr. DeMarco.
The kynurenine pathway is a metabolic pathway leading to the production of nicotinamide adenine dinucleotide (NAD+). Metabolites involved in the kynurenine pathway include tryptophan, kynurenine, kynurenic acid, xanthurenic acid, quinolinic acid, and 3-hydroxykynurenine. The kynurenine pathway is responsible for about 95% of total tryptophan catabolism. Disruption in the pathway is associated with certain genetic and psychiatric disorders.
Polypeptide toxins and many antibacterial peptides, such as colicins or hemolysins, and certain proteins involved in apoptosis, are sometimes considered a separate category. These proteins are water-soluble but can undergo significant conformational changes, form oligomeric complexes and associate irreversibly or reversibly with the lipid bilayer.
=== Sources === This article incorporates text from a free content work. Licensed under CC BY 4.0 (license statement/permission). Text taken from The State of Food Security and Nutrition in the World 2025, Food and Agriculture Organization of the United Nations. This article incorporates text from a free content work. Licensed under CC BY-SA 4.0 (license statement/permission). Text taken from The State of Food Security and Nutrition in the World 2024, Food and Agriculture Organization.
Sources: en.wikipedia.org
== Function == The MAPEG family (Membrane-Associated Proteins in Eicosanoid and Glutathione metabolism) consists of six human proteins, two of which are involved in the production of leukotrienes and prostaglandin E, important mediators of inflammation. Other family members, demonstrating glutathione S-transferase and peroxidase activities, are involved in cellular defense against toxic, carcinogenic, and pharmacologically active electrophilic compounds. This gene encodes a protein that catalyzes the conjugation of glutathione to electrophiles and the reduction of lipid hydroperoxides. This protein is localized to the endoplasmic reticulum and outer mitochondrial membrane where it is thought to protect these membranes from oxidative stress. Four transcript variants of this gene encode one protein isoform.
For example, lung resistance-related proteins, otherwise referred to as major vault proteins, are located on the nuclear membrane of cells and typically mediate nucleocytoplasmic transport. Here, the regulation of compounds between the nucleus and cytoplasm is a process that can be overexpressed by cancer cells to transport DNA-targeted chemotherapeutic drugs away from the nucleus, and essentially restrict these drugs from successfully interacting with their targets. Without reducing the total intracellular chemotherapeutic drug concentration, cancer cells have developed mechanisms to successfully dismantle drug-target interactions and confer resistance to multiple chemotherapeutic drugs. An additional mechanism of resistance interfering with drug-target interaction can be demonstrated by mutations in genes that encode for drug target proteins, such as tubulin. Broadly, tubulin proteins make up intracellular structures known as microtubules that play a fundamental role in cellular shape, division, signaling, and movement, thus making them a particular promising site of target for chemotherapeutic drugs. By altering or inhibiting microtubule dynamics in cancer cells, drugs can prohibit successfully cell division and induce the direct activation of adoptotic pathways. However, mutations that produce physical alterations in tubulin protein structure, can interfere with the several tubulin binding sites and inhibit the effective interaction and activity of these chemotherapeutic drugs.
=== BMSS Medal === In 2002 the BMSS Medal was established by the society “to recognise sustained contributions by individual members of the British Mass Spectrometry Society to the development of mass spectrometry, primarily within the UK.”
==== Pharmacokinetics ==== Nabilone can be readily absorbed from the small intestine into the systemic circulation. The rate and extent of absorption of nabilone are not affected by food intake. It takes around 2 hours to reach its highest concentration in blood. It is distributed extensively and quickly in various body tissues including liver where it is rapidly metabolised into several active metabolites. CYP450 enzymes may also be involved in some of its metabolism. Nabilone is mainly excreted with faeces.
=== Diet === The quantity of food and drink consumed by an individual may play a role in weight management, as may the types of food and drink a person consumes. For example, intake of sweetened drinks such as sodas or juices can lead to increased energy intake that is not neutralized by a decrease in accompanying food intake. Increased portion sizes may also lead to increased energy intake. Food categories such as intake of proteins, carbohydrates, and fats are all important to consider when managing weight. It is also important to have control and understand how certain foods may affect the human body.
Sources: en.wikipedia.org
It is a synthetic cyclic heptapeptide analogue of alpha-melanocyte-stimulating hormone, containing seven amino acids with a lactam ring and a D-configured phenylalanine residue. It is supplied as a lyophilised powder for laboratory research.
The natural hormone is a linear tridecapeptide that is rapidly degraded in circulation. Melanotan-2 is shortened, cyclised, N-terminally acetylated, and carries a D-amino acid substitution, all of which slow enzymatic breakdown.
No national medicines regulator has approved melanotan-2 for therapeutic or cosmetic use. In several jurisdictions it is treated as an unapproved prescription medicine, and its legal classification differs from country to country.
It is a synthetic cyclic heptapeptide modelled on alpha-melanocyte-stimulating hormone. A lactam bridge links two side chains, forming a ring that stabilises the molecule against proteolysis. It belongs to the broader melanocortin peptide family.